0000000000485759

AUTHOR

Lasma Lauberte

showing 4 related works from this author

Influence of metformin on GLUT1 gene and protein expression in rat streptozotocindiabetes mellitusmodel

2010

Metformin improves hyperglycaemia via mechanisms which include activation of AMP-activated protein kinase (AMPK). Recent findings indicate that some metabolic actions of metformin occur also by AMPK-independent mechanisms.To study the action of metformin on expression of GLUT1 glucose transporter in rat streptozotocin model of diabetes mellitus.Streptozotocin-induced rats were treated with metformin while monitoring parameters of carbohydrate and lipid metabolism. GLUT1 mRNA and protein expression in kidneys, heart, liver and muscles were studied by means of real time quantitative RT-PCR and immunohistochemistry correspondingly.Metformin treatment decreased glucose concentration, glycated h…

Maleendocrine systemmedicine.medical_specialtyendocrine system diseasesPhysiologyCarbohydrate metabolismDiabetes Mellitus ExperimentalPhysiology (medical)Internal medicineDiabetes mellitusmedicineAnimalsHypoglycemic AgentsRats WistarGlycated HemoglobinGlucose Transporter Type 1Glucose tolerance testmedicine.diagnostic_testbiologybusiness.industrydigestive oral and skin physiologyGlucose transporternutritional and metabolic diseasesAMPKGeneral MedicineGlucose Tolerance TestStreptozotocinmedicine.diseaseMetforminRatsMetforminDisease Models AnimalGlucoseEndocrinologyGene Expression Regulationbiology.proteinGLUT1businessmedicine.drugArchives of Physiology and Biochemistry
researchProduct

Effects of γ-Butyrobetaine and Mildronate on Nitric Oxide Production in Lipopolysaccharide-Treated Rats

2008

Production of nitric oxide was measured in lipopolysaccharide-treated rats (10 mg/kg, 4 hr) using the electron paramagnetic resonance method. As compared to the control animals, the nitric oxide level in liver of lipopolysaccharide-treated rats increased from 27.6+/-4.7 to 1485+/-129 ng/g tissue, in heart from 4.8+/-0.7 to 271+/-26 ng/g tissue, in blood from 33.6+/-12.4 to 638+/-136 ng/g tissue, in kidney from 3.3+/-0.5 to 356+/-31 ng/g tissue, in brain cortex from 46.0+/-3.4 to 227+/-27 ng/g tissue, in cerebellum from 27.7+/-2.6 to 218+/-30 ng/g tissue, and in testes from 13.8+/-1.1 to 86+/-8 ng/g tissue. Administration of the antiischaemic drug, mildronate (120 mg/kg) caused a significant…

Pharmacologymedicine.medical_specialtyKidneyCerebellumLipopolysaccharidebiologyGeneral MedicineToxicologyIn vitroNitric oxideNitric oxide synthasechemistry.chemical_compoundEndocrinologymedicine.anatomical_structurechemistryAnesthesiaInternal medicineCirculatory systemmedicinebiology.proteinCarnitinemedicine.drugBasic & Clinical Pharmacology & Toxicology
researchProduct

Correction of glycaemia and GLUT1 level by mildronate in rat streptozotocin diabetes mellitus model

2011

Anti-ischaemic drug mildronate suppresses fatty acid metabolism and increases glucose utilization in myocardium. It was proposed that it could produce a favourable effect on metabolic parameters and glucose transport in diabetic animals. Rats with streptozotocin diabetes mellitus were treated with mildronate (100 mg/kg daily, per os, 6 weeks). Therapeutic effect of mildronate was monitored by measuring animal weight, concentrations of blood glucose, insulin, blood triglycerides, free fatty acids, blood ketone bodies and cholesterol, glycated haemoglobin per cent (HbA1c%) and glucose tolerance. GLUT1 mRNA and protein expression in kidneys, heart, liver and muscles were studied by means of re…

Blood Glucosemedicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentClinical BiochemistryBiochemistryStreptozocinDiabetes Mellitus Experimentalchemistry.chemical_compoundInternal medicineDiabetes mellitusDiabetes MellitusmedicineAnimalsBody SizeHypoglycemic AgentsInsulinRNA MessengerRats WistarTriglyceridesGlycated HemoglobinGlucose Transporter Type 1Glucose tolerance testmedicine.diagnostic_testFatty acid metabolismbiologyCholesterolbusiness.industryInsulinFatty AcidsGlucose transporternutritional and metabolic diseasesCell BiologyGeneral MedicineGlucose Tolerance Testmedicine.diseaseRatsEndocrinologychemistrybiology.proteinKetone bodiesGLUT1businessMethylhydrazinesCell Biochemistry and Function
researchProduct

Genetic inactivation of the sigma-1 chaperone protein results in decreased expression of the R2 subunit of the GABA-B receptor and increased suscepti…

2021

There is a growing body of evidence demonstrating the significant involvement of the sigma-1 chaperone protein in the modulation of seizures. Several sigma-1 receptor (Sig1R) ligands have been demonstrated to regulate the seizure threshold in acute and chronic seizure models. However, the mechanism by which Sig1R modulates the excitatory and inhibitory pathways in the brain has not been elucidated. The aim of this study was to compare the susceptibility to seizures of wild type (WT) and Sig1R knockout (Sig1R−/−) mice in intravenous pentylenetetrazol (PTZ) and (+)-bicuculline (BIC) infusion-induced acute seizure and Sig1R antagonist NE-100-induced seizure models. To determine pos…

0301 basic medicinemedicine.medical_specialtyKnockoutGene ExpressionNitric Oxide Synthase Type IISigma-1 receptorConvulsantsAnisolesSigma-1 receptor Knockout GABA-B receptor Seizures Medial habenula NE-100BicucullineHippocampuslcsh:RC321-571Mice03 medical and health sciences0302 clinical medicineDownregulation and upregulationSeizuresInternal medicineGene expressionmedicineAnimalsReceptors sigmaGABA-B receptorGenetic Predisposition to DiseasePentylenetetrazolReceptorlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryMice KnockoutHabenulaSigma-1 receptorPropylaminesSeizure thresholdChemistryMedial habenulaWild typeAntagonistReceptors GABA-A030104 developmental biologyEndocrinologyReceptors GABA-BNeurologyNE-100Pentylenetetrazole030217 neurology & neurosurgerymedicine.drugNeurobiology of Disease
researchProduct